A method to treat inflammatory disorders.
Malfunctions of the immune system are responsible for a series of inflammatory disorders. Two such disorders are rheumatoid arthritis and asthma, encompassing together approximately 23 million Americans. No definitive treatment is currently available for these diseases, and therefore they remain chronic diseases which require life long treatment, accompanied with inconvenient use of drugs together with unwanted side effects. The present invention offers a method to treat inflammation by a molecule that down-regulates the movement of immune cells.
CCL2 is well known to specifically attract T cells. This molecule was found to be involved in various inflammatory responses. In the current technology it is suggested that administration of low levels of CCL2 (rather than its inhibition) may be used to effectively reduce T cell migration and homing into lymph nodes, and as such may be clinically beneficial as an anti-inflammatory agent in inflammatory diseases.